Safety and Efficacy Study Adding GSK2190915 to Mid-dose Inhaled Corticosteroid/Long Acting Beta Agonist Combination Treatment for Asthma

NCT01248975 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

145

Enrollment

INDUSTRY

Sponsor class

Conditions

Asthma

Interventions

DRUG: FP/SAL 250/50mcg BID
DRUG: GSK2190915 200mg QD (AM)
DRUG: GSK2190915 100mg QD (AM)
DRUG: Montelukast 10mg QD (PM)
DRUG: Placebo tablets (2) (AM)
DRUG: Placebo capsule (PM)

Sponsor

GlaxoSmithKline